Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LANADELUMAB-FLYO Cause Post procedural complication? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Post procedural complication have been filed in association with LANADELUMAB-FLYO. This represents 0.5% of all adverse event reports for LANADELUMAB-FLYO.

7
Reports of Post procedural complication with LANADELUMAB-FLYO
0.5%
of all LANADELUMAB-FLYO reports
0
Deaths
6
Hospitalizations

How Dangerous Is Post procedural complication From LANADELUMAB-FLYO?

Of the 7 reports, 6 (85.7%) required hospitalization.

Is Post procedural complication Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LANADELUMAB-FLYO. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does LANADELUMAB-FLYO Cause?

Hereditary angioedema (794) Product dose omission issue (177) Inappropriate schedule of product administration (144) Drug ineffective (137) Headache (126) Weight decreased (125) Weight increased (120) Injection site pain (119) Product use issue (114) Malaise (90)

What Other Drugs Cause Post procedural complication?

ADALIMUMAB (2,494) ETANERCEPT (318) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (244) UPADACITINIB (241) RISANKIZUMAB-RZAA (232) INFLIXIMAB (217) METHOTREXATE (188) TREPROSTINIL (174) HUMAN IMMUNOGLOBULIN G (159) PREDNISONE (157)

Which LANADELUMAB-FLYO Alternatives Have Lower Post procedural complication Risk?

LANADELUMAB-FLYO vs LANREOTIDE LANADELUMAB-FLYO vs LANSOPRAZOLE LANADELUMAB-FLYO vs LANTHANUM LANADELUMAB-FLYO vs LANTUS LANADELUMAB-FLYO vs LANTUS SOLOSTAR

Related Pages

LANADELUMAB-FLYO Full Profile All Post procedural complication Reports All Drugs Causing Post procedural complication LANADELUMAB-FLYO Demographics